Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19


An enzymatically inactivated hemoglobinase from Necator americanus induces neutralizing antibodies against multiple hookworm species and protects dogs against heterologous hookworm infection.

Pearson MS, Bethony JM, Pickering DA, de Oliveira LM, Jariwala A, Santiago H, Miles AP, Zhan B, Jiang D, Ranjit N, Mulvenna J, Tribolet L, Plieskatt J, Smith T, Bottazzi ME, Jones K, Keegan B, Hotez PJ, Loukas A.

FASEB J. 2009 Sep;23(9):3007-19. doi: 10.1096/fj.09-131433. Epub 2009 Apr 20.


Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.

Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, Fay MP, Narum D, Rausch K, Miles AP, Aebig J, Orcutt A, Muratova O, Song G, Lambert L, Zhu D, Miura K, Long C, Saul A, Miller LH, Durbin AP.

PLoS One. 2008 Jul 9;3(7):e2636. doi: 10.1371/journal.pone.0002636.


Enhanced antibody production in mice to the malaria antigen AMA1 by CPG 7909 requires physical association of CpG and antigen.

Mullen GE, Aebig JA, Dobrescu G, Rausch K, Lambert L, Long CA, Miles AP, Saul A.

Vaccine. 2007 Jul 20;25(29):5343-7. Epub 2007 May 25.


Formulation of vaccines containing CpG oligonucleotides and alum.

Aebig JA, Mullen GE, Dobrescu G, Rausch K, Lambert L, Ajose-Popoola O, Long CA, Saul A, Miles AP.

J Immunol Methods. 2007 Jun 30;323(2):139-46. Epub 2007 May 11.


Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria.

Malkin E, Long CA, Stowers AW, Zou L, Singh S, MacDonald NJ, Narum DL, Miles AP, Orcutt AC, Muratova O, Moretz SE, Zhou H, Diouf A, Fay M, Tierney E, Leese P, Mahanty S, Miller LH, Saul A, Martin LB.

PLoS Clin Trials. 2007;2(4):e12. Epub 2007 Apr 6.


Toll-like receptor agonists influence the magnitude and quality of memory T cell responses after prime-boost immunization in nonhuman primates.

Wille-Reece U, Flynn BJ, Loré K, Koup RA, Miles AP, Saul A, Kedl RM, Mattapallil JJ, Weiss WR, Roederer M, Seder RA.

J Exp Med. 2006 May 15;203(5):1249-58. Epub 2006 Apr 24.


An ounce of prevention on a budget: a nonprofit approach to developing vaccines against neglected diseases.

Bottazzi ME, Miles AP, Diemert D, Hotez PJ.

Expert Rev Vaccines. 2006 Apr;5(2):189-98. Review.


A quantitative slot blot assay for host cell protein impurities in recombinant proteins expressed in E. coli.

Zhu D, Saul AJ, Miles AP.

J Immunol Methods. 2005 Nov 30;306(1-2):40-50. Epub 2005 Aug 18.


Quantifying recombinant proteins and their degradation products using SDS-PAGE and scanning laser densitometry.

Miles AP, Saul A.

Methods Mol Biol. 2005;308:349-56. No abstract available.


Extraction and characterization of vaccine antigens from water-in-oil adjuvant formulations.

Miles AP, Saul A.

Methods Mol Biol. 2005;308:293-300. No abstract available.


Determining residual host cell antigen levels in purified recombinant proteins by slot blot and scanning laser densitometry.

Miles AP, Zhu D, Saul A.

Methods Mol Biol. 2005;308:233-42. No abstract available.


Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria.

Malkin EM, Diemert DJ, McArthur JH, Perreault JR, Miles AP, Giersing BK, Mullen GE, Orcutt A, Muratova O, Awkal M, Zhou H, Wang J, Stowers A, Long CA, Mahanty S, Miller LH, Saul A, Durbin AP.

Infect Immun. 2005 Jun;73(6):3677-85.


Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria.

Malkin EM, Durbin AP, Diemert DJ, Sattabongkot J, Wu Y, Miura K, Long CA, Lambert L, Miles AP, Wang J, Stowers A, Miller LH, Saul A.

Vaccine. 2005 May 2;23(24):3131-8.


Montanide ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations.

Miles AP, McClellan HA, Rausch KM, Zhu D, Whitmore MD, Singh S, Martin LB, Wu Y, Giersing BK, Stowers AW, Long CA, Saul A.

Vaccine. 2005 Mar 31;23(19):2530-9.


In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response.

Kennedy MC, Wang J, Zhang Y, Miles AP, Chitsaz F, Saul A, Long CA, Miller LH, Stowers AW.

Infect Immun. 2002 Dec;70(12):6948-60.


Large-scale purification and characterization of malaria vaccine candidate antigen Pvs25H for use in clinical trials.

Miles AP, Zhang Y, Saul A, Stowers AW.

Protein Expr Purif. 2002 Jun;25(1):87-96.


Medicare physician payment reform and the utilization of cardiovascular procedures.

Okunade AA, Miles AP.

J Health Soc Policy. 1999;11(1):37-52.


Supplemental Content

Loading ...
Support Center